FDA
-
-
-
-
-
-
-
Ionis starts Phase 1-2 trial of ION337 for Dravet syndrome
-
-
-
-
-
-
-
Ionis licenses zilganersen to Recordati for ex-U.S. markets
-
-
-
-
-
-
-
Biogen advances IONIS alzheimer's drug after phase 2 study shows cognitive benefit
-
-
-
-
-
-
-
FDA approves high dose SPINRAZA for spinal muscular atrophy
-
-
-
-
-
-
-
FDA accepts Ionis olezarsen application for priority review
-
-
-
-
-
-
-
DAWNZERA gets European Commission approval for hereditary angioedema
-
-
-
-
-
-
-
Ionis receives FDA breakthrough therapy designation for Alexander disease drug
-
328,206 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

